Compass Therapeutics (CMPX) Times Interest Earned (2018 - 2026)
Compass Therapeutics (CMPX) posted Times Interest Earned of -$0.63 for Q1 2026, up 99.65% sequentially from -$179.9 in Q4 2025, and up 92.53% YoY from -$0.32 in Q1 2025.
Compass Therapeutics (CMPX) Times Interest Earned (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported Times Interest Earned for 9 years, with the latest figure at -$0.63 in Q1 2026.
- Quarterly Times Interest Earned rose 92.53% year-over-year to -$0.63 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.31 (up 91.96% YoY) and the FY2025 annual result came in at -$0.92, up 3.36% from the prior year.
- Times Interest Earned rose to -$0.63 in Q1 2026 per CMPX's latest filing, from -$179.9 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.63 in Q1 2026 and troughed at -$179.9 in Q4 2025.
- A 5-year average of -$49.87 and a median of -$22.15 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned sank 2700.98% in 2024, then jumped 98.02% in 2025.
- Over 5 years, Times Interest Earned stood at -$42.96 in 2022, then tumbled by 258.31% to -$153.93 in 2023, then jumped by 95.58% to -$6.8 in 2024, then plunged by 2545.8% to -$179.9 in 2025, then jumped by 99.65% to -$0.63 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$0.63, -$179.9, and -$1.36 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | -2.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.45 |
| Mar 31, 2026 | -0.63 |
| Dec 31, 2025 | -179.90 |
| Sep 30, 2025 | -1.36 |
| Jun 30, 2025 | -2.98 |
| Mar 31, 2025 | -8.37 |
| Sep 30, 2024 | -6.80 |
| Jun 30, 2024 | -150.45 |
| Mar 31, 2024 | -20.37 |
| Dec 31, 2023 | -153.93 |
| Sep 30, 2023 | -115.79 |
| Jun 30, 2023 | -5.37 |
| Mar 31, 2023 | -32.37 |
| Dec 31, 2022 | -42.96 |
| Sep 30, 2022 | -41.99 |
| Jun 30, 2022 | -10.71 |
| Mar 31, 2022 | -23.94 |
| Dec 31, 2021 | 56.28 |
| Sep 30, 2021 | -4.24 |
| Mar 31, 2021 | -51.68 |